Background/Objectives: To determine if consumption of yogurt containing a high dose of probiotic (1 Â 10 10 colony-forming unit per 100 ml), Bifidobacterium animalis subsp. lactis (B. lactis), decreases absences in children 2-4 years attending daycare/ school centers. Subjects/Methods: We conducted a double-blinded, randomized, placebo-controlled, allocation concealment clinical trial in the Washington, DC area. Our active intervention was a strawberry yogurt-based drink supplemented with B. lactis BB-12. The placebo was indistinguishable from the active drink, differing only in absence of the probiotic BB-12.
Introduction
Probiotics are live microorganisms, which when administered in adequate amounts, confer a health benefit on the host (Food and Agriculture Organization of the UN and WHO, 2001) . Probiotics have shown benefits in treatment and prevention of varied diseases, including diarrhea, asthma, necrotizing enterocolitis and allergies (Vanderhoof et al., 1999; Kalliomaki et al., 2001; Rosenfeldt et al., 2002; Mastrandrea et al., 2004; Lin et al., 2005) . However, these studies often tested probiotics in supplement, not food, formats.
Bifidobacterium animalis subsp. lactis (B. lactis), marketed as BB-12, is a commercially available probiotic strain that is considered one of the most well characterized and studied probiotics, particularly in reducing illness in young children. (Black et al., 1989; Alm et al., 1993; Link-Amster et al., 1994; Saavedra et al., 1994; Schiffrin et al., 1995; Obradovic et al., 1996; Kankaanpaa et al., 1998; Phuapradit et al., 1999; Matsumoto et al., 2001; Chouraqui et al., 2004; Amrouche et al., 2006a, b; Taipale et al., 2011) . Long-term consumption of BB-12-fortified formula at levels as high as 240 billion colony-forming unit (CFU) per day has been shown to be safe and well tolerated (Abi-Hanna et al., 1998; Saavedra et al., 2004) . Importantly, a previous study conducted by Weizman et al. (2005) on 201 healthy term infants between the ages of 4 to 10 months at 14 daycare centers in Southern Israel demonstrated positive outcomes from BB-12-fortified formula. Children were solely fed one of three treatments for 12 weeks: a formula fortified with 1.2 Â 10 9 CFU per day of either BB-12 or Lactobacillus reuteri ATCC 55730, or placebo formula containing no added probiotic. The control group reported more days of febrile illness, increased episodes of diarrhea and increased absences from daycare than either group on the probiotic-fortified formulas.
Probiotic products have been reported to generate $15.9 billion in 2008, with more than 500 probiotic food and beverage products being introduced in the past decade (marketsandmarkets.com, 2009) . Despite their popularity, there is a need for controlled studies on specific probiotic strains, in settings and modalities that are similar to how probiotics are actually consumed in the United States (Pedone et al., 1999; Hatakka et al., 2001; Weizman et al., 2005; Lin et al., 2009) . We have previously found that providing an intervention in the form of a yogurt drink greatly increases compliance, and presents parents with a simple alternative to traditional probiotic supplemental pills or capsules (Merenstein et al., 2009) . However, the effectiveness of yogurt supplementation needs further research. The overall goal of this study was to determine whether once daily consumption of a probiotic-supplemented yogurt-based beverage containing BB-12 at a minimum 10 10 CFU per serving could reduce daycare absences in children ages 2-4.
Subjects and methods

Methods
Study design. A double-blinded, randomized, placebocontrolled, patient-oriented trial was conducted. Participants consumed four ounces of active or control drink daily for 90 consecutive days and data were collected via regularly scheduled phone calls. The Georgetown University Institutional Review Board, in Washington, DC, USA approved all aspects of the trial and participants' parents signed informed consent. An independent Data and Safety Monitoring Board met and reviewed data at 25, 50 and 75% completion and all adverse events (AEs). In addition to phone interviews, parents kept daily calendars (diaries). Diary data provided secondary assessment.
Participants. Healthy children between the ages of 2 and 4 years attending daycare center/school at least 3 days per week in the Washington, DC area were recruited into the study. Exclusion criteria were: regular use of medications at initiation of study, lactose intolerance, allergy to strawberry, inability of a parent to speak English or Spanish, active infection, diarrhea, congenital anomalies or chronic disease. Participants were also excluded if they were being breastfed or if parents refused to stop feeding or supplementing other probiotics during the course of the study.
Randomization. The randomization scheme was generated using Stata software (StataCorp LP, College Station, TX, USA) by data managers who were excluded from participant contact (StataCorp, 2005) . Households were randomized in a 1:1 ratio to receive either the active or control drink.
Stratified block randomization was implemented. Children in the same household were assigned to the same drink group. Once eligibility criteria were met, the participant was randomized to one of the two groups, study identification was generated, and group assigned.
Interventions. Both placebo and the active intervention were strawberry-flavored dairy drinks developed at Pennsylvania State University, containing a commercial blend (YFL-702, Chr Hansen, Milwaukee, WI, USA) of the active cultures Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. Control and active drink were identical except that before packaging, the active drink was supplemented with the probiotic BB-12, acquired from Chr Hansen. The frozen, concentrated BB-12 was added to the yogurt drink after fermentation and blending with the corn syrup, sugar, pectin water slurry. After addition, the BB-12 was allowed to melt and was dispersed by stirring before packaging. Subjects were allocated four fluid ounces (112 g) per day of their allocated drink. To verify the viable count of probiotic in the drink, product was analyzed weekly by pour plating suitable dilutions on selective MRS agar (de Man, Rogosa and Sharpe) followed by anaerobic incubation at 37 1C for 48 h. Random colonies counted as B. animalis subsp. lactis were picked and identified by PCR using subspecies specific primers (Ventura et al., 2001) .
The yogurts were transported by the study personnel to the participants' homes in coolers packed with ice and equipped with a VWR Digital Refrigerator/Freezer Thermometer with Alarm (VWR International, West Chester, PA, USA). Before each delivery, the study personnel arranged and confirmed a mutually convenient time with the participants to ensure they would be home to receive the yogurt. This ensured that the participants could place the yogurt into their home refrigerators immediately on receipt. Parents gave the yogurt to the children; consumption was confirmed via the daily diary and follow-up calls.
Blinding. The appearance, taste, nutritional composition (proteins, carbohydrates, lipids and energy) and packaging (one-quart bottles) of the active and control products were identical. Study personnel, including clinicians, research assistants and office personnel, were blinded. Dr Roberts and the Pennsylvania State University dairy plant staff assigned labels and were therefore not blinded to the product's identity, but did not have any participant contact. All of these measures led to successful true allocation concealment and proper blinding.
Outcome measures. The primary outcome was missed days of school because of illness. To assess this outcome, parents were specifically asked during the phone calls, 'How many days of daycare/school did your child's school have?' and 'How many days did he/she miss in the past 2 weeks because of them not feeling well, if any?' Parents were also asked to record these data in the daily diaries.
Secondary outcomes per group included parental reports of: presence of diarrhea; amount of yogurt consumed on a daily basis; consistency of stools; presence of respiratory infection; missed parental work; doctor visits; and type of illnesses.
AEs were collected at all regularly scheduled phone calls and in the interim, parents had access to a 24-h phone number for immediate reports. AEs were defined by parents as events that were not usual for their child. All AEs were also included in illness reports. Serious AEs were defined as any incidences of death, life-threatening event, hospitalization, prolongation of hospital stay or an event resulting in permanent disability.
Statistical analysis
The sample size calculation is based on the primary outcome variable, days of absence from daycare. Assuming that consuming BB-12 yogurt would result in a 20% reduction in absences, a type I error of 0.05 is postulated, with a power of 80%. A previous study reported a mean (s.d.) of 5.8 (4.5) days of illnesses among Finnish children aged 1 to 6 years, during a 7-month follow-up (Hatakka et al., 2001) . Using this latter estimate of the mean and the estimate of 4.5 for the s.d. from the Finnish study, the estimated minimum sample size without dropout is 74 to detect a 20% reduction in absences. Thus, our goal was enroll 90 per group to account for dropout.
Statisticians blinded to the group allocation conducted the statistical analyses. Furthermore, all research personnel were blinded while examining initial data. Baseline demographics were compared between the groups using independent t-test for continuous variables and w 2 test for categorical variables.
All analyses of primary and secondary outcomes were conducted on an intention-to-treat basis. Incidence rate ratios were calculated using the number of events divided by number of days in study. A P-value of o0.05 was considered to indicate statistical significance. All P-values were twosided. Intercooled Stata 9.2 for Windows was used to run the analyses (StataCorp, 2005) .
Results
Active drink Viable counts of B. animalis subsp. lactis and pH of the probiotic-containing yogurt-based beverage were evaluated over 60 days of incubation at 4 1C. Data presented in Figure 1 demonstrate that although the population of viable BB-12 in the product showed a typical decline in viable cells over time, the yogurt drink delivered at least 1 Â 10 10 CFU per 100 ml serving of BB-12 at the end of its 30-day shelf life. The data suggest the useful shelf life could be extended beyond 30 days. Furthermore, informal sensory analysis indicated the product remained acceptable for at least 50 days (data not shown). The pH of the yogurt remained constant over time ( Figure 1 ) indicating minimal post-manufacture acidification, a potential quality flaw in refrigerated yogurts. The maintenance of viability and pH of the yogurt for over 50 days suggested that the shelf life of this product could be extended beyond 30 days.
Recruitment, enrollment and participant flow During the enrollment period from 15 September 2008 to 20 May 2009, 343 participants left voice messages stating interest in the study, Figure 2 . Of 278 participants screened, 90 were not eligible for the study. A total of 172 participants were enrolled (68% of participants who were screened). The active group included 91 participants and the control group included 81.
Baseline demographics
Randomization worked appropriately in that there were no significant differences in the baseline characteristics between the two groups, Table 1 . There were a total of 151 families and 172 children represented in the study. The majority of the participants in both groups were self-reported by their caregivers as being white and living in a household with an annual income over $100 000. Although not statistically significant, the active group did have a higher percentage of white participants and higher household income. Additionally, over 15% of the participants had at least one parent of Hispanic descent, with 16% of the interviews being conducted in Spanish (data not shown). in compliance between the active group (93%) and the placebo group (88%) was not significant (P ¼ 0.305). There was no association between a parent believing one's child was in the active group and actually being in the active group (P ¼ 0.632).
Compliance
Primary outcomes
The primary outcome, missed days of school because of illness per 100 days, was similar in both the active (2.54 days absent/100 school days) and control groups (2.42 days absent/100 school days) (P ¼ 0.873), Table 2 .
Secondary outcomes
There were also no significant differences among the secondary outcomes measured in the study, Table 2 . Parents in the active group reported 0.79 missed days of work/100 days compared with 0.94 in the control group (P ¼ 0.552). Runny nose was the most common symptom, with rates of 12.25 days affected/100 days reported in the active group and 14.26 days affected/100 days in the control group (P ¼ 0.458).
Sensitivity analysis
All participants were very healthy, as assured by the exclusion criteria. At baseline, the overall self-reported health on a scale of 1-10 with 1 ¼ very unhealthy and 10 ¼ extremely healthy, was 8.85 in the active group and 8.90 in the placebo group. As a result of this, we also examined a subset of participants, (N ¼ 59) with baseline scores below 9. The effect sizes were often large among the groups but only constipation was significantly different between the groups, with rates of 2.76 days affected/100 days reported in the active group compared with 0.68 days affected/100 days in the control group (P ¼ 0.036). Interestingly, days with allergies was 2.82 days affected/100 days in the active group compared with 8.59 in the control group and complaints of breathing problems was 0.66 days affected/100 days in the active group compared with 4.43 in the control group. These differences, however, did not reach statistical significance.
Adverse events
In all, 11 total AEs were reported for the study and there were no statistically significant differences between the groups, with 8 in the active group and 3 in control group, Table 3 . Five subjects had diarrhea or loose stools in the active group compared with zero in the control group. There were no serious AEs in either group reported throughout the entire study.
Discussion
The probiotic-containing yogurt-based beverage we studied did not decrease absences because of illnesses in daycare/ school for healthy children ages 2-4 years. Additionally, there were no differences between the groups in any secondary outcomes. These results leave us with a few alternatives that deserve further discussion. The most obvious conclusion is that BB-12 supplemented in a yogurt with the two starter cultures provides no benefit in reducing daycare absences. We based our sample size on a Daycare study D Merenstein et al previous trial with a different probiotic that was given in milk (Hatakka et al., 2001) . However, the milk was given three times a day by daycare staff, an approach nearly impossible in the United States. The previously discussed Weizman study of BB-12 also found increased absences in the control group (Weizman et al., 2005) . However, both of these studies were conducted outside of the United States, in very different settings than United States daycares, supplementation was not via yogurt, and compliance was guaranteed by daycare workers. We were interested in a study that measured effects under conditions more typical of real-life use, such as use of product stored in home refrigerators and consumed without study personnel observation. Although we had high compliance compared with traditional medicines, compliance in a community study is not comparable to such structured settings.
It is also possible that we experienced a type II error because our effect size difference was overly ambitious. The BB-12 yogurt does appear to have an impact on children's gastrointestinal tract as more children in the BB-12 group had reported gastrointestinal symptoms. When we examined the subset of less healthy children at baseline there was more constipation in the BB-12 group. Additionally, our study population was extremely healthy children. It is likely in that in this population, a smaller impact on absences from school would be expected and in order to show an impact a much larger sample size is needed. We had anticipated higher rates of illness and missed school.
Another concern is with the control product that was chosen. Our placebo is regular yogurt, including the two active starter cultures. The two previously discussed daycare studies used placebos with no active cultures. We choose our placebo in order to isolate the impact BB-12 may have on pediatric health but it is possible that unfortified regular yogurt also impacts health. Use of a third group consuming non-fermented acidified yogurt would have enabled us to differentiate effects that yogurt with active cultures might have imparted. In support of this theory, our overall rates of illness and absences were lower than historical cohorts.
The choice of BB-12 for this study was guided by several factors. The gastrointestinal tract contains a complex commensal microbiota that contributes to homeostasis. The intestinal microbiota includes hundreds of species of facultative and obligate anaerobes (Tuohy et al., 2005) . Supplemental probiotics may help regulate the microbiota when disturbed by outside influences (Engelbrektson et al., 2006) . To establish that a probiotic has an effect on intestinal health, isolation of the probiotic from the stool is considered an important trait. Several studies document the ability of BB-12 ability to survive intestinal transit, which was considered an important criterion for use (Fukushima et al., 1997; Malinen et al., 2002; Ouwehand et al., 2004; Bartosch et al., 2005) . Furthermore, BB-12 has been shown to impact immune function as well as impact absences from daycare for infants (Fukushima et al., 1998; Weizman et al., 2005; Kekkonen et al., 2008) .
Although the outcome data do not support our primary outcome that yogurt containing BB-12 could reduce absences of children from daycare or school, some useful information was gained from this study. We demonstrated that BB-12 could remain stable at high levels in yogurt for over 50 days, with no evidence of post-acidification. In addition, we demonstrated that this study population readily consumed the probiotic yogurt, indicating a successful means of delivery of high-dose BB-12. Finally, the minimum number of AEs (11 minor, self-limited events were reported with over 12 000 days of product consumption) supports the safety of the product.
In interpreting the results from this study, it is important to recognize that we studied a functional food, not a medicinal product. Our intent was to evaluate this food as it would be used by consumers. Therefore, we chose to rely on parental reporting of their child's health parameters rather than on examinations of children by physicians. A limitation of this method is that these assessments are subjective and vary by evaluator. Compliance was also measured by self-report. However, our intention-to-treat analysis assured that lack of compliance did not bias our results. We felt this was especially appropriate for a food product, which is unlikely to be consumed without missed servings in real-life situations. Finally, our population tended to be of high socioeconomic status. Although this population does not reflect the national population as a whole, this population is often the one interested in purchasing these types of products.
Our randomized clinical trial showed that BB-12 fortified yogurt is safe and well tolerated in children 2-4 years old but did not reduce daycare absences or illnesses. We believe it is crucial for other probiotic products on the market to be tested independently and in patient-oriented settings. The need for well-designed, objective studies, which assess patient-oriented efficacy and safety outcomes is tremendously important in the field of probiotics, especially considering the plethora of products being advertised and sold in the marketplace. Although this study does not support the value of this probiotic yogurt in reducing absences from daycare or school, it does demonstrate that the product is well tolerated, that viable counts can remain high for prolonged periods of time, and that compliance is extremely high with this mode of ingestion.
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